The agreement was announced following the successful quality audit and will see Recipharm aseptically pack single-use vaccines, used to treat a severe infectious disease that affects both young children and infants.

The containers will be efficiently filled using Recipharm's specialist blow-fill-seal (BFS) capabilities, creating products that are quick to distribute and simplifying administration for healthcare providers.

Recipharm plans to recruit over 30 members of staff between 2022 and 2026 as the product scales towards commercial production.

Yves Buelens, General Manager at Recipharm's facility in Kaysersberg, commented: "We are very proud to be supporting a big pharma partner in the delivery of a vital vaccine to the market.

This deal is indicative of Recipharm's successful and ongoing product portfolio diversification. We've invested heavily into new capabilities that have built on our BFS expertise and as a result, strengthened our biotech offering. We are now in a position to welcome new biopharma projects to the Kaysersberg site."

Recipharm is investing almost EUR 14 million into its vaccine manufacturing offering at the site.

Located in the Alsace region of France, Kaysersberg is one of Recipharm's specialist sterile manufacturing facilities which had been previously dedicated to the exclusive production of sterile liquids for therapeutic areas, including eye care and ear drops.

This facility has been inspected and approved by multiple regulatory agencies across the globe including ANSM (EU-GMP), FDA and Brazil's ANVISA. It also holds a number of approvals for its environmental management systems and occupational health and safety management system.

Contact information:
Marcus Smith, Head of Communications at Recipharm, marcus.smith@recipharm.com 
For media enquiries, please contact Gabriella White at ramarketing: gabriella.white@ramarketingpr.com,+44191 222 1242, ramarketingpr.com

About Recipharm
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing almost 9,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical product development and development and manufacturing of medical devices. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm's annual turnover is approximately SEK 11 billion. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden.

For more information on Recipharm and our services, please visit www.recipharm.com